Thromb Haemost 2007; 97(01): 81-87
DOI: 10.1160/TH06-04-0226
Wound Healing and Inflammation / Infection
Schattauer GmbH

Danaparoid sodium reduces ischemia/reperfusion-induced liver injury in rats by attenuating inflammatory responses

Naoaki Harada
1   Department of Biodefense Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya
,
Kenji Okajima
1   Department of Biodefense Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya
,
Hidefumi Kohmura
2   Department of Diagnostic Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto
,
Mitsuhiro Uchiba
2   Department of Diagnostic Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto
,
Tsutomu Tomita
3   Cine-Science Laboratory Co., Ltd., Tokyo; Japan
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 27. April 2006

Accepted after resubmission 09. November 2006

Publikationsdatum:
28. November 2017 (online)

Preview

Summary

This study was undertaken to examine the mechanism by which danaparoid sodium (DS), a heparinoid that contains mainly heparan sulfate, prevents reperfusion-induced hepatic damage in a rat model of ischemia/reperfusion (I/R)-induced liver injury. Administration of DS significantly reduced liver injury and inhibited the decrease in hepatic tissue blood flow in rats. DS attenuated hepatic I/R-induced increases in hepatic tissue levels of tumor necrosis factor (TNF) and myeloperoxidase (MPO) in vivo. In contrast, neither monocytic TNF production nor neutrophil activation was inhibited by DS in vitro. DS enhanced I/R-induced increases in levels of calcitonin-gene related peptide (CGRP), a neuropeptide released from sensory neurons, and of 6-ketoprostaglandin (PG) F, a stable metabolite of PGI2, in liver tissues. The therapeutic effects of DS were not seen in animals pretreated with capsazepine, an inhibitor of sensory neuron activation. The distribution of heparan sulfate in the perivascular area was significantly increased by DS administration in this rat model. DS significantly increased CGRP release from isolated rat dorsal root ganglion neurons (DRG) in vitro, while DX-9065a, a selective inhibitor of activated factor X, did not. DS enhanced anandamide-induced CGRP release from DRG in vitro. These observations strongly suggested that DS might reduce I/R-induced liver injury in rats by attenuating inflammatory responses. These therapeutic effects of DS might be at least partly explained by its enhancement of sensory neuron activation, leading to the increase the endothelial production of PGI2.